nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-23DA6A62·Framework v5.10·Pipeline v0.4·Evaluated 02 Nov 2026·OECD: 3.2 Clinical medicine·Subfield: Genetics·Basis: Full text·Type: Cross-sectional study

Long-Term Real-World Outcomes in Patients with Hereditary Angioedema Receiving Lanadelumab for 3 or More Years.

Lumry et al.Lumry, Davis-Lorton, Soteres et al.·2025·International archives of allergy and immunology·10.1159/000546987 ↗

Primary claim

In conclusion, treatment with lanadelumab LTP for at least 3 years reduced the severity and frequency of attacks and improved QoL in patients with HAE.

Tentative · uncontrolled retrospective observations among persistent users cannot identify a causal treatment effect
In brief

Long-term lanadelumab observations document improvement among persistent users, but the uncontrolled retrospective design cannot establish treatment effects.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Unlikely to hold — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

UNLABELLED: <p>Introduction: Hereditary angioedema (HAE) is a rare genetic disorder characterized by unpredictable, painful swelling attacks that significantly impair patients' quality of life (QoL). Clinical trials of lanadelumab led to its approval for long-term prophylaxis in patients with HAE; however, real-world data on long-term lanadelumab use in patients with HAE are limited. This analysis describes real-world outcomes of patients with HAE who have received lanadelumab as long-term prophylaxis for ≥3 years.

METHODS: From January 2023 to January 2024, investigators collected data from the Adelphi Wave II Disease Specific Programme™, a real-world, cross-sectional survey of physicians and their patients with HAE in the USA. Physicians retrospectively reported attack frequency, attack severity, and QoL before lanadelumab initiation, at 12, 24, and 36 months post initiation, and at the time of the survey.

RESULTS: Physicians reported data on 51 patients who had received lanadelumab for ≥3 years. Before lanadelumab initiation, physicians reported attack severity as mild in 49.0% of patients and very severe in 8.2%; at 36 months post lanadelumab initiation, 62.5% of patients experienced mild attacks and none experienced very severe attacks in the preceding year. The proportion of patients experiencing ≥1 attack per month on average decreased from 54.0% before lanadelumab initiation to 9.8% at the time of the survey. The proportion of patients with good or excellent QoL increased from 68.6% before lanadelumab initiation to 88.2% at the time of the survey.

CONCLUSION: In this real-world HAE study, patients treated with lanadelumab for ≥3 years experienced improvements in attack frequency, disease severity, and QoL. </p>.

Key Claims

Primary finding · Tentative

In conclusion, treatment with lanadelumab LTP for at least 3 years reduced the severity and frequency of attacks and improved QoL in patients with HAE.

Unlikely to hold — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

uncontrolled retrospective observations among persistent users cannot identify a causal treatment effect

Discussion, final paragraph (conclusion)
Quote verified
Secondary · Supported

The proportion of patients experiencing at least 1 attack per month on average decreased from 54.0% (27 of 50) prior to lanadelumab initiation to 9.8% (5 of 51) at the time of the survey.

reported counts support the descriptive decrease among selected long-term users, despite retrospective reporting and no comparator

Results, Attack Frequency
Quote verified
Secondary · Tentative

The proportion of patients with good or excellent QoL increased from 68.6% before lanadelumab initiation to 88.2% at the time of the survey.

retrospective, unvalidated physician-rated QoL limits certainty about patients' experienced improvement

Abstract Results; Results, Health-related QoL
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Longer observation extends rare disease evidence

The analysis reports outcomes before treatment and at 12, 24, and 36 months among 51 patients receiving lanadelumab for at least three years. This adds longer-term descriptive observations to the earlier 12-month analysis.

↳ Methods, Assessments; Introduction, final paragraph; Results

#reporting

Explicit denominators make descriptive findings traceable

Outcome proportions generally include their numerators and denominators, and the analysis states that varying sample sizes reflect missing or incomplete reporting. The printed counts support the reported attack-frequency and QoL percentages.

↳ Methods, Statistical Analysis; Results, Attack Frequency and Health-related QoL

#positioning

Findings connected to established clinical evidence

The Discussion compares the observations with HELP, EMPOWER, earlier Adelphi outcomes, and other real-world studies. It also identifies recall, selection, missingness, and subjective assessment as limitations.

↳ Discussion, literature-comparison and limitations paragraphs

Limitations

#methodological rigour

Causal conclusion exceeds the uncontrolled design

The final conclusion attributes improvements to lanadelumab, but the single-arm retrospective survey cannot separate treatment effects from regression to the mean, natural history, or other changes.

↳ Methods, Study Design and Statistical Analysis; Discussion, final paragraph

#methodological rigour

Persistent user selection limits broader applicability

Eligibility requires at least three years of continuous lanadelumab-only prophylaxis. Patients who discontinued, switched, or added another prophylactic treatment are excluded, so the findings describe continuers rather than everyone starting treatment.

↳ Methods, Study Design

#methodological rigour

Retrospective physician ratings constrain outcome certainty

Severity and QoL were reconstructed from medical records and physician judgment, without validated patient-reported QoL measures. Missing reporting and uncharacterized measurement error further limit confidence in the trajectories.

↳ Methods, Assessments and Statistical Analysis; Discussion, limitations paragraph

Does this match your read? Add your assessment ↓

Nabu Commentary

The study adds longer-term descriptive observations among 51 patients who remained on lanadelumab, with reported counts supporting the direction of the attack-frequency changes. Its principal constraint is the combination of no comparator or confounding-control strategy with a final conclusion that attributes improvements to treatment. Eligibility restricted to persistent users and retrospective, unvalidated physician-rated outcomes further constrain interpretation. The Discussion engages relevant evidence and names important limitations, but those qualifications do not narrow the final causal claim.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.5±0.1

Contribution
2.8

The analysis extends earlier 12-month observations to selected patients receiving lanadelumab for at least three years. Existing trial and four-year real-world evidence make this an incremental addition rather than resolution of a distinct uncertainty.

Introduction, final paragraph; Discussion, comparison paragraphs
Methodological Rigour
2.0

The retrospective physician survey supplies descriptive outcomes but lacks a comparator or confounding-control strategy for its causal conclusion. Selection of long-term continuers, unvalidated physician-rated outcomes, and unexamined missingness further constrain interpretation.

Methods, Study Design, Assessments, and Statistical Analysis; Discussion, limitations and final paragraphs
Reporting
3.1

The article's organization and explicit denominators make the descriptive findings traceable. The final conclusion nevertheless presents treatment effects more strongly than the design supports.

Results, Attack Frequency and Health-related QoL; Discussion, final paragraph
Positioning
2.8

The Discussion connects the findings to HELP, EMPOWER, earlier Adelphi observations, and other real-world studies. Its explicit limitations are not carried through to the final causal conclusion.

Discussion, literature-comparison, limitations, and final paragraphs

Lower confidence on Contribution — domain match limited.

Reliability

Caveats4 of 4 checks


Results checkClean

The reported numbers and statistics are consistent with the stated results.

Reporting and transparencyNoted

The attack-frequency categories defined in Methods differ from those reported in Results. Ethics review, sponsorship, conflicts of interest, and a named data-access route are disclosed.

Conflict of interest: declared · Ethics approval: declared · Data availability: declared

Reference IntegrityClean

24 references in manuscript 22 of 22 checkable references found in an index 2 are books, websites or datasets — counted, but not index-checkable

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 02 Nov 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Metabolic and endocrine · Endocrine, metabolic, blood, and immune disorders
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesCatch-all cause
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The claim rests on one retrospective, physician-reported cross-sectional survey of 51 patients with no control group and acknowledged selection and recall bias, so it is shown once in a small real-world sample without independent confirmation.

From the paper
“will further aid treatment decisions and improve outcomes in patients”

The paper names a real-world use of its findings, aiding treatment decisions, but does not specify a profession, organisation or setting that would act on them.

Pathway

Allergists and immunologists managing hereditary angioedema patients could use these long-term data to support continuing lanadelumab prophylaxis and inform long-term treatment decisions.

Barrier

The uncontrolled, retrospective, physician-reported design with 51 patients, missing data, and selection and recall bias limits confidence for treatment decisions without validated patient-reported confirmation.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks

    Riedl, Farkas, Aygören-Pürsün, et al. · 2024 · Clinical medicine

    Primary claim

    Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo.

    Well-supported
    Evidence Score
    4.2±0.2
    Reliability
    No concerns
  2. Efficacy and Safety of Donidalorsen for Hereditary Angioedema

    Riedl, Tachdjian, Lumry, et al. · 2024 · Clinical medicine

    Primary claim

    Donidalorsen at a dose of 80 mg administered subcutaneously every 4 or 8 weeks significantly reduced the hereditary angioedema attack rate

    Supported
    Evidence Score
    4.0±0.1
    Reliability
    Caveats
  3. CRISPR-Based Therapy for Hereditary Angioedema

    Cohn, Gurugama, Magerl, et al. · 2024 · Clinical medicine

    Primary claim

    NTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema.

    Tentative
    Evidence Score
    3.6±0.1
    Reliability
    Caveats

How the rubric works →